Tobevibart

6 trials 1 recruiting Orphan designation

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

1 Recruiting

5 Completed trials

1 Sponsors

9 Countries

Phase III

Phase II

Phase III: 2 Phase II: 4

Indications tested

Hepatitis D 4 Chronic hepatitis B 2

Sponsors using this IMP

Vir Biotechnology Inc. 6

All trials

6 total

A Study to Evaluate Tobevibart+Elebsiran in Participants with Chronic HDV Infection Not Virologically Suppressed with Bulevirtide Recruiting

2024-519282-22-00 Phase III 6 countries Vir Biotechnology Inc.
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended

2024-520062-54-00 Phase II 8 countries Vir Biotechnology Inc.
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Ended

2024-515919-22-00 Phase III 3 countries Vir Biotechnology Inc.
A Study to Evaluate Investigational Therapies in Chronic Hepatitis D Virus Infection. Ended

2024-512203-40-00 Phase II 6 countries Vir Biotechnology Inc.
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects wi… Ended

2024-513177-48-00 Phase II 2 countries Vir Biotechnology Inc.
A Study to Evaluate Investigational Therapies in Chronic Hepatitis B Virus Infection Ended

2024-513176-17-00 Phase II 2 countries Vir Biotechnology Inc.

Showing 1–6 of 6 trials

← All drugs A–Z